Delving into the Latest Updates on DMAb-ZK190 with Synapse

Overview

Basic Info

Drug Type

DNA encoding mab

Synonyms-

Target

ZIKV E protein

Action

inhibitors

Mechanism

ZIKV E protein inhibitors(ZIKV E protein inhibitors)

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Zika Virus Infection

Originator Organization

Guizhou University

Active Organization-

Inactive Organization

Guizhou University

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Author: Kudchodkar, Sagar B ; Bah, Mamadou ; Durham, Amy C ; Park, Daniel H ; Broderick, Kate ; Esquivel, Rianne N ; Corti, Davide ; Choi, Hyeree ; Ramos, Stephanie ; Patel, Ami ; Mendoza, Janess ; Humeau, Laurent ; Shaheen, Shareef ; Allen, Jeffrey W ; Asija, Kanika ; Smith, Trevor R F ; Borole, Piyush ; Chen, Jing ; Stettler, Karin ; Muthumani, Kar ; Weiner, David B ; Beltramello, Martina ; Guibinga, Ghiabe ; Yan, Jian

Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.

100 Deals associated with DMAb-ZK190

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Zika Virus Infection	Preclinical	China	Guizhou University	01 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data